17 / 17
Page 63
allied
academies
J Clin Exp Tox 2017 | Volume 1 | Issue 2
Toxicology and Pharmacology
November 01-02, 2017 | Toronto, Canada
International Conference on
Nanomaterial drug products: Manufacturing and analytical perspectives
Christie M Sayes
Baylor University, USA
T
he increasing use of nanotechnology, including
nanoparticles,inthepreparationofdrugproductsrequires
both manufacturing and analytical considerations in order to
establish the quality metrics suitable for performance and
risk assessment. A range of different nanoparticle systems
exists including (but not limited to) nano-drugs, nano-
additives and nano-carriers. These systems generally require
more complex production and characterization strategies
than conventional pharmaceutical dosage forms. The
advantage of using nanoparticle systems in pharmaceutical
science is that the effective and desired function of the
material can be designed through modern manufacturing
processes. The systematic nomenclature allows for greater
understanding of the drug product under evaluation based
on available data from other nanoparticle reports. Analytical
considerations of nano-drugs, nano-additives and nano-
carriers and the way in which they are measured are directly
connected to quality control. Ultimately the objective is to
consider the entire nano-drugs, nano-additives and nano-
carriers product life cycle with respect to its manufacture,
use, and eventual fate. The tools and approaches to address
the needs of these products exist; it should be the task of the
pharmaceutical scientists and those in related disciplines to
increase their understanding of nanomedicine and its novel
products.
e:
Christie_sayes@baylor.edu